Genetic mutations in TAR DNA-binding protein 43 (TARDBP, also known as TDP-43) cause amyotrophic lateral sclerosis (ALS), and an increase in the presence of TDP-43 (encoded by TARDBP) in the cytoplasm is a prominent histopathological feature of degenerating neurons in various neurodegenerative diseases. However, the molecular mechanisms by which TDP-43 contributes to ALS pathophysiology remain elusive. Here we have found that TDP-43 accumulates in the mitochondria of neurons in subjects with ALS or frontotemporal dementia (FTD). Disease-associated mutations increase TDP-43 mitochondrial localization. In mitochondria, wild-type (WT) and mutant TDP-43 preferentially bind mitochondria-transcribed messenger RNAs (mRNAs) encoding respiratory complex I subunits ND3 and ND6, impair their expression and specifically cause complex I disassembly. The suppression of TDP-43 mitochondrial localization abolishes WT and mutant TDP-43-induced mitochondrial dysfunction and neuronal loss, and improves phenotypes of transgenic mutant TDP-43 mice. Thus, our studies link TDP-43 toxicity directly to mitochondrial bioenergetics and propose the targeting of TDP-43 mitochondrial localization as a promising therapeutic approach for neurodegeneration. npg
ALS is the most common motor disease characterized by progressive motor neuron degeneration in the brain stem and spinal cord 1 , and FTD is the second-most common form of early-onset dementia, caused by neuron loss in the frontal and temporal cortex 2 . The vast majority of ALS or FTD cases, referred to as sporadic ALS or FTD, are not genetically transmitted, and their causes remain unknown. Currently, there is no effective treatment for either ALS or FTD.
TDP-43 is a small, ubiquitously expressed RNA-and DNA-binding protein that contains two tandem RNA-recognition motifs, RRM1 and RRM2 (ref. 3) . Previous studies have revealed that TDP-43 primarily binds mRNA and regulates post-transcriptional RNA processing, including RNA splicing, transportation and translation [4] [5] [6] . Autosomal-dominant mutations in TDP-43 are associated with sporadic and familial ALS 7, 8 , and the redistribution of TDP-43 from the nucleus to cytoplasm has been recognized as a pathological hallmark for most forms of ALS and for the most frequent subtypes of FTD 9, 10 . In fact, the mislocalization of TDP-43 to the cytoplasm also represents a key pathological feature of other major neurodegenerative diseases, including Alzheimer's disease 11, 12 , Parkinson's disease 13 and Huntington's disease 14 .
It still remains controversial whether the loss of TDP-43 function via nuclear depletion or gain of function by adverse effect of cytoplasmic TDP-43 causes neuronal loss in ALS and FTD. Notably, previous studies have revealed that nuclear depletion is not required for TDP-43 neuronal toxicity 15, 16 , and that cytoplasmic TDP-43 is sufficient to cause neurodegeneration 17 . This suggests an important role for cytoplasmic TDP-43 in disease progression. However, both the pathogenic mechanisms of cytoplasmic TDP-43 and its subcellular organelle targets remain largely unknown.
RESULTS

TDP-43 accumulates in mitochondria in ALS and FTD
We first investigated the co-localization of TDP-43 with various neuronal organelles in human spinal cord and frontal cortex tissue samples obtained from individuals with ALS and FTD, respectively, relative to those from age-matched healthy individuals. Both spinal cord motor neurons and cortical neurons in the control cases demonstrated mainly nuclear TDP-43 localization, whereas ALS motor neurons and FTD cortical neurons both showed characteristically high levels of cytoplasmic TDP-43 accumulation ( Fig. 1a-d) .
Notably, cytoplasmic TDP-43 co-localized with mitochondrial markers in many ALS spinal cord motor neurons or FTD cortical neurons, but minimally overlapped with markers of Golgi, endoplasmic reticulum, lysosome, autophagosome, endosome or peroxisome ( Fig. 1a-d and Supplementary Fig. 1 ). Despite its low abundance, cytoplasmic TDP-43 in control human motor neurons and cortical neurons also significantly co-localized with mitochondria ( Fig. 1a-d and Supplementary Fig. 1 ).
We further isolated highly purified mitochondria with preserved membranes from human spinal cord and cortical tissues ( Supplementary Fig. 2a,b) and found TDP-43 present in mitochondria from all samples (Fig. 1e,f) . There was a markedly higher expression of TDP-43 in mitochondria from ALS or FTD than in those from age-matched controls. Subsequent sub-mitochondrial fractionation analysis revealed that mitochondrial TDP-43 was exclusively present in the inner mitochondrial membrane (IMM), and not in the outer mitochondrial membrane (OMM), intermembrane space (IMS) or matrix ( Fig. 1g,h) . Immuno-electron microscopy (immuno-EM) analysis of isolated mitochondria and biopsied human cortex confirmed the main localization of TDP-43 in IMM cristae ( Fig. 1i and Supplementary Fig. 2c (e,f) Representative immunoblot and quantification (n = 3) of TDP-43 levels in mitochondria isolated from age-matched controls (n = 6) and sporadic ALS (n = 8) spinal cords (e), or age-matched controls (n = 6) and sporadic FTD (n = 7) cortices (f). (g,h) Representative immunoblot (n = 3) of TDP-43 in sub-mitochondrial fractions prepared from ALS spinal cords (g) and FTD cortices (h). (i) Immuno-EM of TDP-43 in mitochondria from sporadic ALS spinal cord (left) or sporadic FTD cortex (right). Red arrowheads, immunogold-labeled TDP-43. Right, quantification using thin EM sections with 50-nm thickness. n = 8, 6, 6 and 6, respectively. Throughout, data are means ± s.e.m., representative of triplicate independent experiments. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001.
labeling than did those from age-matched controls. We also isolated mitochondria from freshly collected mouse tissue samples of spinal cord and cortex and treated them with trypsin and digitonin to permeabilize OMM but not IMM. The OMM proteins mitofusin (MFN) 2 and mitochondrial fission factor (MFF) were digested by trypsin alone, and the IMS-facing IMM proteins TIM23 (encoded by Timm23) and optic atrophy (OPA) 1 were digested by trypsin after OMM permeabilization, whereas TDP-43 and the matrixfacing IMM proteins cytochrome c oxidase (COX) IV and F 1 β (also known as ATP5B) remained unchanged under all these conditions ( Supplementary Fig. 2d ). Similarly to COXIV and F 1 β, TDP-43 could be digested by trypsin after complete membrane permeabilization via 4-(1,1,3,3-tetramethylbutyl)phenylpolyethylene glycol (triton X-100). TDP-43 also resides exclusively in the IMM fraction of mouse mitochondria (Supplementary Fig. 2e ).
ALS-associated mutations increase TDP-43 mitochondrial localization
We next determined whether disease-associated mutations in TDP-43 affected its mitochondrial localization. We first examined TDP-43 expression in mitochondria isolated from primary human fibroblasts that were derived from individuals with ALS bearing the TDP-43 mutation G298S or A382T (G298S or A382T fibroblasts) and from age-matched healthy individuals (normal human fibroblasts, NHFs). Mito  OMM  IMS  IMM  Matrix   A315T  WT  A315T  WT  A315T  A315T  WT  A315T  WT   Mito  OMM  IMS  IMM  Matrix   WT  A315T  WT  A315T  WT  A315T  A315T  WT  A315T  WT   Spinal cord   hTDP-43  TOM20  HSP60  Cyto c  TIM23   WT   e   Brain   NHF1  G298S  A382T  NGF1  G298S  A382T  NHF1  G298S  A382T  NHF1  G298S  A382T  NHF1 G298S A382T in freshly isolated mitochondria from mouse brain after mitochondrial import assay. (g) Representative immunoblot and quantification (n = 3) of rTDP-43 in freshly isolated mitochondria from mouse brain after incubation with rTDP-43 at indicated times followed by trypsin and digitonin co-treatment. (h) Immuno-EM analysis of rTDP-43 in purified mouse brain mitochondria after mitochondrial import assay (no post-import treatment). Red arrowheads, immunogold-labeled TDP-43. Right, quantification using thin EM sections with 50-nm thickness. n = 14 for WT and n = 16 for A315T. Data are means ± s.e.m., representative of triplicate experiments. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. *P < 0.05, ***P < 0.001, ****P < 0.0001. In g, *P < 0.05, as compared to WT TDP-43.
npg TDP-43 mutations in G298S and A382T fibroblasts were confirmed by genomic DNA sequencing ( Supplementary Fig. 2f ). Similarly to NHFs, fibroblasts with G298S or A382T mutations exhibited the predominantly nuclear localization of TDP-43 without cytoplasmic accumulation ( Supplementary Fig. 2g ). Whereas all fibroblasts displayed comparable expression of total TDP-43 ( Supplementary  Fig. 2h ), G298S and A382T fibroblasts demonstrated significantly higher levels of mitochondrial TDP-43 than did NHFs ( Fig. 2a and Supplementary Fig. 2i ). We also compared WT and mutant TDP-43 mitochondrial localization in human embryonic kidney (HEK) 293 cells or brain and spinal cord tissue samples from transgenic mice overexpressing WT or mutant human TDP-43. Consistently, despite similar levels in total lysates, exogenously expressed human G298S, A315T or A382T TDP-43 showed greater mitochondrial expression than did human WT TDP-43 ( Fig. 2b,c) . Exogenously expressed or endogenous human WT and mutant TDP-43 were still present in the IMM fraction ( Fig. 2d,e ) and digestible by trypsin after IMM, but not OMM, permeabilization (data not shown).
We then employed a cell-free mitochondrial-import assay using Flag-tagged recombinant WT or mutant human TDP-43 protein (rTDP-43), and isolated mouse brain mitochondria. All human rTDP-43 were soluble, uncleaved and unmodified post-translationally (data not shown). The widely used biotin-labeled recombinant F 1 β precursor protein (pF 1 β) was included as a positive control 18 , and recombinant GFP was employed as a negative control (data not shown). pF 1 β contained a cleavable signal sequence that was cleaved off after import to generate the shorter mature F 1 β (mF 1 β) ( Fig. 2f) . Similarly to mF 1 β, WT rTDP-43 survived co-treatment with digitonin and trypsin after import ( Fig. 2f ), which demonstrates its successful import into the innards of the IMM. rTDP-43 bearing G298S, A315T or A382T demonstrated higher import efficiency than did WT rTDP-43 ( Fig. 2g) . Imported WT and mutant rTDP-43 were both completely digestible by trypsin after triton X-100 permeabilization (data not shown). Further immuno-EM analysis confirmed the IMM cristae localization of imported WT and mutant rTDP-43, as well as the greater import of disease-associated mutant rTDP-43, relative to the WT version ( Fig. 2h) .
TDP-43 mitochondrial localization depends on internal motifs
TDP-43 remains uncleaved after import, and no cleavable presequence is identified in TDP-43 by the online bioinformatics tools TargetP 19 or Mitoprot 20 , which suggests that TDP-43 might use internal signals 21 . Mitochondrial internal signals are typically composed of a stretch of continuous hydrophobic amino acids 22 , and six such stretches (M1-M6) are present in TDP-43 ( Fig. 3a , M1-6) . The deletion of M1, M3 or M5 significantly inhibited rTDP-43 import and reduced mitochondrial localization of exogenously expressed TDP-43 ( Fig. 3b,c) . Given that M1 and M3 segments were conserved across species (Supplementary Fig. 3a) , we synthesized two peptides PM1 (YGRKKRRQRRRAQFPGACGL) and PM3 (YGRKKRRQRRRSKGFGFVRF) in which the M1 or M3 motif was fused to a TAT peptide to enhance permeability 23 . PM1 and PM3, but not control peptides (cPMs, a mixture of YGRKKRRQRRRAAQGFGCPL and YGRKKRRQRRRGRFFKSFG, scrambled M1 and M3 fused to TAT, respectively), suppressed rTDP-43 import and reduced mitochondrial TDP-43 in HEK293 cells and primary neurons, as compared to untreated cells and neurons ( Fig. 3d-f ). The fusion of M3, M5 and, especially, M1 with the unrelated cytosolic protein GFP was sufficient to facilitate its mitochondrial targeting ( Fig. 3g and Supplementary Fig. 3b ). npg Mitochondrial TDP-43 inhibits translation of ND3 and ND6 mRNAs The IMM residence of TDP-43 prompted us to examine whether TDP-43 binds mitochondria-transcribed mRNAs ( Fig. 4a) . RNA immunoprecipitation (IP) with or without prior cross-linking using mouse brain mitochondria revealed that TDP-43, but not the RNAbinding domain lacking negative control COXIV (data not shown), significantly pulled down mRNAs of ND3, ND5, ND6, COXI, COXIII, CYTB and A6, whereas other mRNAs were enriched only slightly, at levels comparable to 12S or 16S rRNAs ( Fig. 4b) . All mutant versions of TDP-43 precipitated similar mRNAs, with abundances comparable to those of WT TDP-43 ( Fig. 4c,d) .
Mitochondrial-transcribed mRNA levels are not affected by TDP-43 overexpression (Supplementary Fig. 3c ). We investigated the effect of TDP-43 on mitochondrial translation in HEK293 cells by the azidohomoalanine (AHA) incorporation assay in the presence of emetine to block cytosolic translation. The synthesis of ND3 and ND6 (ND3/6) was significantly reduced by WT TDP-43 overexpression ( Fig. 4e) , consistently with the preferential binding of TDP-43 to their mRNAs. The steady-state levels of ND3/6, but not of most mitochondrial-encoded subunits of oxidative phosphorylation (OXPHOS) complexes, were indeed decreased by WT TDP-43 in comparison with control cells (Fig. 4f) . The WT-TDP-43-induced reduction in the synthesis or expression of ND3/6 could be blocked by the deletion of M1. TDP-43 has no global effect on the translation of all mitochondria-encoded proteins (Fig. 4e,f) . TDP-43 expression did not alter the sedimentation patterns of mitochondrial ribosome 28S subunit MRPS18B or 39S subunit MRPL44 in sucrose gradients of isolated mitochondria, which suggests that there is no effect on overall mitochondrial ribosome assembly ( Supplementary Fig. 3d ). However, further RNA distribution analysis found that, in contrast npg to a high degree of sedimentation with the 55S ribosomal complex in control cells, additional peaks of ND3/6, but not of COXI, mRNA between 28S and 55S complexes could be induced by WT TDP-43, but not ∆M1, overexpression (Supplementary Fig. 3e ).
As compared to WT TDP-43, all mutant TDP-43s caused further reductions of ND3/6 expression ( Fig. 4f,g) . Notably, M1 deletion or treatment with PM1 increased ND3/6 expression to levels similar to control cells or NHFs. PM3 was not tested because of the localization of M3 in the TDP-43 RNA-binding motif (Fig. 3a) and the mild toxic effect of PM3 on cells (data not shown). As compared to aged-matched control human tissues, ALS spinal cords or FTD cortices exhibited reduced levels of ND3/6 ( Fig. 4h and Supplementary Fig. 3f) .
Mitochondrial TDP-43 impairs OXPHOS complex I Consistent with the specific inhibitory effect of TDP-43 on the expression of complex I subunits ND3/6, WT TDP-43 overexpression caused reduced expression and function of complex I, as well as a slight disassembly of complex I-comprised supercomplexes, in comparison to control cells. These effects were exacerbated by the overexpression of G298S, A315T or A382T mutant TDP-43, but prevented by M1 deletion (Fig. 5a,b and Supplementary Fig. 4a,b) . The disassembly and dysfunction of complex I was also observed in G298S or A382T fibroblasts, and PM1 treatment significantly restored complex I assembly and function to levels comparable to NHFs (Fig. 5c,d) . Notably, TDP-43-induced complex I disassembly and dysfunction could also be alleviated by the simultaneous overexpression of both ND3 and ND6, but not by ND3 or ND6 individually ( Supplementary Fig. 4c and Fig. 5e ).
Substantial mitochondrial dysfunction (including reduced mitochondrial membrane potential (m∆ψ), oxygen-consumption rate (OCR) and ATP levels) accompanied by mitochondrial fragmentation were all observed in HEK293 cells that overexpressed WT or mutant npg TDP-43 ( Supplementary Fig. 4d ), and in G298S or A382T fibroblasts ( Fig. 5f,g) . As compared to WT TDP-43, mutant TDP-43 caused more severe mitochondrial abnormalities. WT or mutant TDP-43-induced mitochondrial dysfunction and fragmentation could be prevented completely by M1 deletion or treatment with PM1. Notably, although no basal cell death was observed, G298S or A382T fibroblasts exhibited increased vulnerability to oxidative stress relative to NHFs, which could also be abolished by PM1 treatment (Fig. 5h) .
Mitochondrial localization is crucial for TDP-43 toxicity WT TDP-43 overexpression resulted in mitochondrial fragmentation and dysfunction preceding neuronal death in cultured rat primary neurons, all of which were exacerbated by G298S, A315T or A382T, but completely abolished by M1 deletion or PM1 treatment (Supplementary Fig. 5 ). We also reprogrammed NHFs and A382T fibroblasts to induced pluripotent stem cells (iPSCs), after which they were sequentially differentiated into induced neuronal progenitor cells (iNPCs) and human neurons (control and A382T human neurons, Supplementary Fig. 6a-e ). Both control and A382T human neurons were indistinguishable in TDP-43 nuclear localization, neuronal morphology and viability ( Supplementary Fig. 6f,g) . However, as compared to control human neurons, A382T human neurons exhibited substantial mitochondrial fragmentation, mitochondrial dysfunction and increased vulnerability to oxidative stress, which could be alleviated by PM1 treatment (Supplementary Fig. 6g-i) .
As expected, M1 deletion was also sufficient to abolish mitochondrial abnormalities and neuronal death induced by TDP-43 WT or A315T overexpression in control human neurons (Supplementary Fig. 6j ). Neuron-specific bicistronic lentiviruses encoding both TDP-43 and mitoDsRed2 (a widely used red fluorescent protein specifically localized in mitochondria) were stereotactically injected into mouse cortices (Fig. 6a) . As compared to WT TDP-43, TDP-43 A315T caused further mitochondrial fragmentation and increased neuronal death (as evidenced by cleaved caspase-3 staining), which could be blocked by M1 deletion (Fig. 6b,c) . Although neurodegeneration has been reported consistently in TDP-43 A315T hemizygous transgenic mice, but not in TDP-43 WT hemizygous transgenic mice [24] [25] [26] [27] [28] , both exhibited similar human TDP-43 expression ( Fig. 2c) . We treated TDP-43 A315T mice with PM1 by continuous subcutaneous infusion and confirmed that PM1 reached the central nervous system and substantially reduced mutant TDP-43 in the mitochondria (Supplementary Fig. 7a-c) . PM1 could be detected in all mitochondrial compartments (Supplementary Fig. 7d) . Consistent with the substantial protective effect against the reduction in ND3/6 expression, m∆ψ, OCR and complex I assembly ( Fig. 6d-f) , PM1 almost completely prevented the loss of cortical and motor neuron cell bodies, axons and/or synapses (as evidenced by denervated neuromuscular junction (NMJ)) in TDP-43 A315T mice (Fig. 6g,h and Supplementary Fig. 7e,f) . Notably, mitochondrial fragmentation and neuropathologies such as phospho-TDP-43 positive inclusions and astrogliosis in TDP-43 A315T mice disappeared after PM1 infusion (Supplementary Fig. 7g-j) . Remarkably, skeletal muscle atrophy and phenotypes (including gait abnormality, impaired performance on rotarod and defects in movement) noted in TDP-43 A315T mice, could also be alleviated by PM1 and restored to levels comparable to those in nontransgenic WT mice (Fig. 6i,j, Supplementary Fig. 8 and Supplementary Videos 1-3) . Of note, the deletion of M1 has no effect on TDP-43 half-life, dimerization or its binding to nonmitochondrial mRNA targets (Supplementary Fig. 9a-d) .
DISCUSSION
Consistent with a previous ultrastructural study 29 , here we show that some TDP-43 accumulates in mitochondria in ALS and FTD. TDP-43 aggregation, cleavage, ubiquitination and phosphorylation were reported in ALS and FTD 9, 30 . Despite being highly phosphorylated, mitochondrial TDP-43 is soluble and uncleaved ( Supplementary  Fig. 9e-g) . Phospho-TDP-43-positive inclusions highly co-localize with mitochondria, ubiquitin-positive, compact or skein-like TDP-43 inclusions partially overlap, and mitochondrial co-localized TDP-43 shows little ubiquitination (Supplementary Fig. 9h,i) . Given that TDP-43 pre-inclusions are reportedly highly phosphorylated, but not ubiquitinated 29, 31 , mitochondria-associated TDP-43 probably represents this pre-inclusion population of pathologic TDP-43. G298S is present in the M5 motif, and as compared to G298S, phosphorylation-mimicking mutant G298D causes further increase of mitochondrial localization, whereas phosphorylation-ablation mutant G298A exhibited similar mitochondrial localization as WT TDP-43 (Supplementary Fig. 9j ). It is worth investigating whether other disease-associated TDP-43 mutations residing within or out of mitochondrial internal motifs also increase its mitochondrial localization through phosphorylation.
Similarly to ALS and FTD neurons, cultured neurons expressing mutant TDP-43 exhibited TDP-43 mislocalization and formation of puncta in cell bodies, and neurites co-localized with mitochondria ( Supplementary Fig. 10a-d) . Both were abolished by M1 deletion or PM1 treatment, which suggests that mitochondrial TDP-43 is a possible upstream regulator of TDP-43 mislocalization. However, because TDP-43 deficiency alone is sufficient to cause neuronal loss 32, 33 , the contribution of TDP-43 nuclear depletion to mitochondrial TDP-43 accumulation could not be ruled out. TDP-43 with inactivated nuclear-localization signal substantially co-localizes with mitochondria ( Supplementary Fig. 10e ), which indicates that mitochondrial localization is an intrinsic property of cytoplasmic TDP-43. TDP-43 binds mitochondria-transcribed mRNA and regulates mitochondrial translation. Mitochondrial-translation machinery resides in immediate proximity to matrix-facing IMM 34 . Therefore, the matrix-facing IMM localization of TDP-43 supports its functional role inside mitochondria. IMM proteins with internal sequences are imported across the OMM through the TOM complex via import receptor subunit TOM70 and across the IMM by the TIM22 complex 22 . As expected, TIM22, but not TIM23, co-precipitated TDP-43, and knockdown of TIM22, but not TIM23, substantially reduced TDP-43 mitochondrial localization (Supplementary Fig. 10f,g) . These results, together with the finding that both TOM20 and TOM70 co-precipitated TDP-43, indicate that TDP-43 mitochondrial import depends on the TOM and TIM22 complex. TDP-43 import depends on ∆ψ (Supplementary Fig. 10h ). Considering that molecular chaperones are usually needed to unfold protein before and during import 22 , perhaps the final localization of TDP-43 in mitochondria depends on multiple factors, including, but not limited to, TOM and TIM22 complexes, ∆ψ and chaperones.
Recombinant TDP-43 could bind the ND3 probe with diminished efficiency when all G and U(s) in UG repeats are mutated to A(s) (Supplementary Fig. 10i) , which suggests previously identified UG repeats [35] [36] [37] [38] as potential binding sites. TDP-43 mainly pulls down ND3/6 mRNAs and inhibits their translation. It can be expected that increased levels of mitochondrial TDP-43 specifically cause complex I disassembly and dysfunction. Notably, mitochondrial TDP-43 impairs the mitochondrial ribosomes that load onto ND3/6 mRNAs, which suggests one possible mechanism by which TDP-43 regulates mitochondrial translation. The co-expression of both ND3 and ND6 was sufficient to alleviate TDP-43-induced complex I disassembly and dysfunction, which supports ND3/6 as specific targets of TDP-43 in mitochondria. Indeed, mutations in ND3/6 are directly associated with neurological disorders and cause complex I deficiency 39, 40 . Given that the assembly of respiratory complexes and mitochondrial dynamic are highly interrelated 41, 42 , it is feasible that, in addition to regulating mitochondrial bioenergetics, TDP-43 could affect both mitochondrial morphology and movement [43] [44] [45] [46] . TDP-43-induced mitochondrial fragmentation or trafficking deficit could be abolished by inhibiting its mitochondrial localization (Supplementary Fig. 11a-c) , which points to them as downstream effects. Mitochondrial-trafficking deficit induced by TDP-43 could be alleviated by the inhibition of mitochondrial fragmentation 46 , which indicates the impairment of mitochondrial movement possibly even downstream of mitochondrial fragmentation.
The physiological function of TDP-43 is still unclear. Either knockdown of TDP-43 or reduced mitochondrial TDP-43 by PM1 increases ND3/6 expression, but has no effect on other complex I subunits or complex I assembly ( Supplementary Fig. 11d,e ). Disease-associated mutations in TDP-43 do not change its IMM localization and binding efficiency to ND3/6 mRNAs. The toxicity of WT or mutant TDP-43 on mitochondria and neurons is likely due to excess mitochondrial TDP-43, which may explain why PM1 treatment, which reduced, but did not completely abolish, mitochondrial TDP-43, restored mitochondrial and neuronal function in A315T mice to levels comparable to NTG mice.
Mitochondrial dysfunction precedes TDP-43-induced neuronal death, and mitochondria are involved in almost all types of cell death, including apoptosis and necrosis 47, 48 . In cultured rat primary neurons overexpressing TDP-43, we found fewer cleaved caspase-3-positive neurons than SYTOX-green-positive neurons, which suggests potentially different types of neuronal death caused by TDP-43. Therefore, it is of further interest to investigate the potential role of mitochondrial dysfunction in the mediation of TDP-43-induced neuronal death by apoptotic and nonapoptotic mechanisms. Unlike rat primary neurons, human neurons derived from A382T fibroblasts exhibit normal neuronal viability. Considering that age or age-associated phenotypes are usually lost after fibroblast reprogramming 49, 50 , it is possible that the level of mitochondrial TDP-43 in young iPSCs derived from human neurons bearing A382T mutation is insufficient to reach the threshold to cause neuronal death, and that age-dependent mitochondrial TDP-43 accumulation is required for mutant TDP-43 neuronal toxicity.
In summary, here we present a novel mechanism of TDP-43 toxicity wherein TDP-43 resides in mitochondria specifically impairing OXPHOS complex I via the preferential binding of mitochondrialtranscribed ND3/6 mRNAs and by inhibiting their translation to cause mitochondrial dysfunction and neurodegeneration ( Supplementary  Fig. 12) . Notably, the suppression of TDP-43 mitochondrial localization abolishes the toxicity of WT or mutant TDP-43 on mitochondria and neurons, which thus provides a rationale for targeting TDP-43 mitochondrial localization as a new therapeutic approach to neurodegeneration linked to TDP-43.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Immunocytochemistry and immunofluorescence of mouse and human spinal cord. The use of all human tissue samples was approved by the University Hospitals Institutional Review Board (IRB) for human investigation at University Hospitals Case Medical Center at Cleveland. Human spinal cord tissues obtained postmortemly from University Hospitals of Cleveland were fixed, and 6-µm-thick consecutive sections were prepared as we described before 51 (Supplementary Table 1) . Immunocytochemistry was performed by the peroxidase anti-peroxidase protocol 51 . For immunofluorescence staining, deparaffinized and re-hydrated tissue sections were washed briefly three times with distilled H 2 O and placed in 1X antigen decloaker (Biocare, Concord, CA). The sections were then subject to antigen retrieval under pressure using Biocare's Decloaking Chamber by heating to 125 °C for 10 s and cooling to 90 °C for 30 s, followed by heating to 22 psi at 128 °C and cooling to 0 psi at 94 °C. After the temperature decreased to 30 °C, the sections were gradually rinsed with distilled H 2 O for five times. The sections were then blocked with 10% normal goat serum (NGS) for 30 min at RT and incubated with primary antibodies in PBS containing 1% NGS overnight at 4 °C. After three washes with PBS, the sections were incubated in 10% NGS for 10 min, and then with Alexa Fluor conjugated secondary antibody (Life Technologies, Grand Island, NY) (1:300) for 2 h at room temperature in dark. Finally, the sections were rinsed three times with PBS, stained with DAPI for nuclei, washed again with PBS for three times and mounted with Fluoromount-G mounting medium (Southern Biotech, Birmingham, AL).
Expression vectors, recombinant proteins, peptides, antibodies and chemicals.
MitoDsRed2 (Clontech, Mountain View, CA) and lentiviral packing plasmids (PCMV-dR8.2 and PCMV-VSVG from Addgene, Cambridge, MA) were obtained. Flag-tagged TDP-43 constructs were generated by cloning TDP-43 into PCMV-3Tag-1a (Agilent, Santa Clara, CA) or pCMVTnT (Promega, Madison, WI). GFP fused with M1, M3 or M5 constructs were generated on the basis of PCMV-3Tag-9a (Agilent, Santa Clara, CA). TDP-43 mutations were all generated using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA). Bicistronic lentiviral constructs expressing both MitoDsRed2 and TDP-43 were generated by cloning TDP-43 and mitoDsRed2 into pLVX-Puro (Clontech) and replacing PCMV promotor with mouse synapsin 1 promoter. ND3 or ND6 gene in nuclear format with the addition of mitochondrial targeting sequence from subunit VIII of human cytochrome c oxidase to the 5′-terminus (and the addition of myc tag to the 3′-terminus) were directly synthesized and subcloned into pcDNA3.1 + (GenScript) ( Supplementary Table 2 ). Primers used for RT-PCR or real time-PCR (Life Technologies, Grand Island, NY) and RNAi oligonucleotides (Sigma St. Louis, MO; Tim22 esiRNAi: EHU160361-20UG and TIM23 esiRNAi: EHU106141-20UG) were obtained (Supplementary Table 2 ). His-tagged recombinant human TDP-43 was obtained from ATGEN (Gyeonggi-do, South Korea), and Flag-tagged recombinant human TDP-43 were synthesized in rabbit reticulocyte system by coupled transcription and translation with biotin-lysyl-tRNA using pCMVTnT constructs (Promega, Madison, WI). cPM, PM1 and PM3 peptides (with or without FITC labeling) in which M1 or M3 motif or scrambled M1 or M3 motif fused to the C terminus of the protein transduction domain (YGRKKRRQRRR) of the human immunodeficiency virus TAT protein to enhance peptide delivery and permeability as described 23 were obtained from NeoBiolab (Woburn, MA) or Biomatik (Wilmington, DE). Primary antibodies used in this study are listed in Supplementary Table 3 . All chemicals were obtained (Sigma-Aldrich, St. Louis, MO).
Embryonic primary cortical neuron, HEK293 cells and primary human
fibroblasts culture and transfection. Primary cortical neurons were isolated from E18 Sprague Dawley rats (Harlan, Indianapolis, IN), as previously described 52 with modifications. Briefly, rat brains were dissected out in HBSS (Life Technologies, Grand Island, NY) and stored in Hibernate E (BrainBits, Springfield, IL) supplemented with 2% B27 (Life Technologies, Grand Island, NY). Under a dissecting microscope, the meninges were removed completely with fine forceps and cortices were dissected out. Cortices were then digested in 0.25% trypsin for 15 min at room temperature, followed by brief incubation in Opti-MEM (Life Technologies, Grand Island, NY) supplemented with 10% FBS and 50 units per ml DNAse I (Worthington-Biochem, Lakewood Township, NJ). Digested cortices were further dissociated by gentle trituration with pipette until the cell suspension was homogenous and no large pieces of tissue remain visible. Cortical neurons were finally collected and seeded on poly-l-lysine and laminin-coated coverslips or chamber slides (BD, Franklin Lakes, NJ), 35-mm dishes or 24-well plates, and cultured as we described before 46 . HEK293T cells from American Type Culture Collection (ATCC, Manassas, VA) were grown in DMEM medium (Life Technologies, Grand Island, NY), supplemented with 10% FBS and 1% penicillin-streptomycin in 5% CO 2 in a humid incubator at 37 °C. Primary human fibroblasts from four age-matched healthy subjects and two patients with ALS bearing TDP-43 mutations (only 2 lines are available) were obtained from Coriell Institute for Medical Research (NINDS collection). Primary fibroblasts were grown in minimum essential medium (Life Technologies) containing nonessential amino acids and 2 mM glutamine, supplemented with 10% or 15% (v/v) FBS, in 5% CO 2 in a humid incubator at 37 °C, as we described before 53 . HEK293 cells and primary human fibroblasts were tested and confirmed to be free of mycoplasma contamination. Neurons were all transfected by NeuroMag (OZ Biosciences, San Diego, CA), and HEK293T cells and primary fibroblasts were transfected with lipofectamine 2000 (Life Technologies, Grand Island, NY) according to the manufacturer's protocol. For co-transfection, a 3:1 ratio (mitoDsRed2 or TDP-43:GFP) was applied.
Generation of iPSCs using human fibroblasts and differentiation of iPSCs to human neurons. For reprogramming, two lines of NHFs and TDP-43 G298S
or A382T human fibroblasts were cultured in DMEM supplemented with 10% FBS (Life Technologies) and GlutaMAX (Life Technologies). Fibroblasts were reprogrammed using CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life Technologies) according to the manufacturer's instructions using irradiated MEFs (iMEF) as feeder cells. iPSCs were routinely cultured on iMEFs in hESC medium (DMEM/F12 with GlutaMAX (Life Technologies), 10% KnockOut Serum Replacement (Life Technologies), 0.1 mM 2-mercaptoethanol (Life Technologies), 1× nonessential amino acids (Life Technologies) and 10 ng per ml bFGF (Sigma-Aldrich). For differentiation, iPSCs were first cultured on matrigel-coated 6-well plates in TeSR1 E8 medium (Stem Cell Technologies) and then differentiated into induced neuronal progenitor cells (iNPCs) using StemDiff Neural Induction Medium and AggreWell 800 (both from Stem Cell Technologies) according to instructions. iNPCs were selected using Neural Rosette Selection Medium and further expanded using neural progenitor medium (both from Stem Cell Technologies). For characterization of iPSCs and iNPCs, immunofluorescence staining was carried out as previously described 54 , using antibodies against TRA-1-81 (1:150), Nanog (1:150), SSEA3 (1:10) and SSEA4 (1:10). For alkaline phosphatase (AP) staining, Alkaline Phosphatase Staining Kit II (Stemgent) was used. iNPCs were differentiated into human neurons using Axol iNPCs differentiation and maturation kits (Axol, Cambridgeshire, UK) following the manufacturer's protocol. Taken briefly, iNPCs cells were first seeded on 24-or 48-well plates or 24-well seahorse plates coated with Axol SureBondXF in Axol Plating-XF medium. 24 h after plating, cells were transferred into neuronal differentiation medium (Axol Neuronal Differentiation-XF medium). After 72 h, half of the neuronal differentiation medium was replaced with neuronal maturation medium (Axol Neuronal Maintenance-XF medium), followed by half neuronal maturation medium change every 4 d. iPSCs and iNPCs used in the study were tested and confirmed to be free of mycoplasma contamination. iPSC-derived neurons were also transfected by NeuroMag (OZ Biosciences, San Diego, CA).
Cellular and mitochondrial fractionation. Mitochondria were isolated as described before 46 . Taken briefly, cells were homogenized in IB-1 solution (IB-1: 225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA, 20 mM HEPES; pH = 7.4), and tissues were homogenized in IB-1 with 0.5% BSA. The total homogenate (H) was centrifuged at 600g for two times at 4 °C for 5 min. Subsequently, the supernatant (S1) was collected and centrifuged at 7,000g at 4 °C for 10 min to obtain enriched mitochondrial fraction, and the supernatant (S2) was collected. The enriched mitochondrial fraction was washed in IB-2 solution (225 mM mannitol, 75 mM sucrose, 20 mM HEPES; pH = 7.4) for cell mitochondria and IB-2 containing 0.5% BSA for tissue mitochondria, followed by centrifugation at 9,000g for 10 min. The pellets were suspended in MRB buffer (250 mM Mannitol, 0.5 mM EGTA, 5 mM HEPES; pH 7.4) to obtain crude mitochondrial fraction (cM). The crude mitochondrial fraction was further overlaid on top of 8 ml Percoll medium (225 mM mannitol, 25 mM HEPES, 1 mM EGTA and 30% Percoll (vol/vol); pH = 7.4) and subjected to centrifugation at 95,000g for 30 min at 4 °C in a SW40 Ti rotor. The pellet was suspended in MRB buffer again, followed by centrifugation at 6,300g for 10 min at 4 °C to obtained purified mitochondria (pM). Nuclear fraction was isolated and purified by nuclear extraction reagents (Thermo Scientific, Waltham, MA).
For sub-mitochondrial compartment fractionation, isolated pure mitochondria were suspended in isolation medium (225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA, 20 mM HEPES; pH = 7.4) with digitonin at 0.12 mg digitonin per mg mitochondria and stirred gently on ice for 15 min. Then digitonin-treated samples were diluted two times using the isolation medium and centrifuged at 9,000g for 10 min to get supernatant A, followed by pellet resuspension in isolation buffer and sonication for 30 s on ice. Then the solution was sonicated and centrifuged at 6,500g for 10 min, followed by centrifugation at 144,000g for 60 min, to sediment the inner membrane vesicles, and the supernatant was collected as matrix fraction. Supernatant A was centrifuged at 144,000g for 60 min to sediment the outer membrane vesicles as pellets, and the supernatant was collected as inner membrane space fraction. system with appropriate primer pairs using SYBR Green master mix (Life Technologies, Grand Island, NY). See Supplementary Table 2 for primers used (A8 and ND4L have not been specifically measured and amplified owing to their short sequences).
Mitochondrial nascent protein synthesis in HEK293 cells. HEK293 cells expressing Flag-tagged TDP-43 were cultured in DMEM culture medium without methionine (Life Technologies, Grand Island, NY) for 1 h, followed by pretreatment with 0.1 mg per ml emetine for 10 min and co-treatment with 0.1 mg per ml emetine and l-azidohomoalanine (AHA, Life Technologies, Grand Island, NY) for 4 h. After pulse labeling, cells were harvested, followed by mitochondrial fractionation. Isolated mitochondria were lysed with 1% SDS in 50 mM Tris-HCl, pH 8.0, followed by centrifugation at 10,000g for 10 min. The supernatant was incubated with avidin-dynabeads (Life Technologies, Grand Island, NY) at room temperature for 30 min. After the removal of beads, the supernatant was subjected to Click-it assay (Life Technologies, Grand Island, NY). Taken briefly, 200 µg mitochondria proteins were labeled with PEG4carboxamide-6-azidohexanyl-biotin in a 160 µl volume system, and total proteins were precipitated and extracted by methanol and chloroform. After centrifugation at 18,000g for 5 min, the total protein pellets were collected and dissolved by 1% SDS in 50 mM Tris-HCl for western blot.
Fractionation for mitochondrial ribosomes and their loading on RNAs.
Isolated mitochondria were lysed in lysis buffer (260 mM sucrose, 100 mM KCl, 20 mM MgCl 2 , 10 mM Tris-Cl pH 7.5, 1% Triton X-100, 5 mM β-mercaptoethanol and protease inhibitor) on ice for 20 min. Lysates were centrifuged at 9,400g for 30 min at 4 °C. Then supernatants were loaded on 11 ml 10-30% continuous linear sucrose gradient (50 mM Tris-Cl, 100 mM KCl, 10 mM MgCl 2 ) and centrifuged at 20,400 rpm for 15 h in a Beckman SW41-Ti rotor at 4 °C. After centrifugation, 13 fractions were collected from the top and used for further immunoblot and qRT-PCR analysis.
Blue-native PAGE and immunoblot analysis. Blue-native gel electrophoresis was performed with NativePAGE Bis-Tris Gel system (Life Technologies, Grand Island, NY). Briefly, isolated mitochondria containing 10 µg of mitochondrial proteins were resuspended in sample buffer and solubilized with 2% digitonin (Sigma-Aldrich) for 30 min on ice. Insolubilized pellets were removed by centrifugation for 30 min at 18,000g. The supernatant was collected, and 5% G-250 sample additive was added. Samples were loaded to 3-12% precast Bis-Tris gradient gels (Life Technologies, Grand Island, NY), followed by electrophoresis at a voltage of 40 V with light blue running buffers at 4 °C. For regular immunoblot analysis, purified mitochondria, cells or tissues were lysed with cell lysis buffer (Cell Signaling, Danvers, MA) plus 1 mM PMSF and protease inhibitor cocktail (Roche, Nutley, NJ). Equal amounts of 10 µg total protein extract were resolved by SDS-PAGE and transferred to Immobilon-P (Millipore, Billerica, MA). After blocking with 10% nonfat dry milk, primary and secondary antibodies were applied as previously described 56 , and the blots were developed with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA). Frozen human thoracic spinal cord tissues from six age-matched healthy and eight patients with sALS were obtained from NICHD Brain and Tissue Bank (Supplementary Table 1 ).
RNA-protein in vitro binding assay. ND3 RNA probe (5′-UCCACCCCUUA CGAGUGCGGCUUCGACCCUAUAUC-3′) and mutant ND3 RNA probe (5′-UCCACCCCUUACAAAUAAAGCUUCGACCCUAUAUC-3′) were purchased from GenScript (Piscataway, NJ). RNA-protein binding was performed in 20 µl reactions containing 1 µM RNA probe. The binding conditions were 10 mM Tris at pH 7.5, 10 mM HEPES at pH 7.5, 20 mM KCl, 2 mM MgCl2, 1.5 mM DTT, 5% glycerol. After incubation at room temperature for 30 min, samples were run at 100 V on a pre-electrophoresed 6% polyacrylamide gel containing 0.5× TBE for 1 h in ice-water bath. Gel was stained by SYBR Green solution (Life Technologies, Grand Island, NY) for 20 min at RT. Then stained gel was rinsed with water for three times and visualized by EpiChemi II Darkroom (UVP, Upland, CA).
Lentivirus production, stereotaxic injection and cryosection.
Lenti-X 293T cells (Clontech, Mountain View, CA) were transfected with bicistronic lentiviral construct and two helper plasmids: PCMV-dR8.2 and PCMV-VSVG at 6 µg, 4.5 µg and 1.5 µg of DNA per 10-cm plate using PerFectin (Genlantis, San Diego, CA). 48 h after transfection, culture medium was centrifuged at 780g for 30 min and filtered at a 0.45-µm pore size. Filtered medium was further laid on the top of 20% sucrose followed by centrifugation in Beckman SW-28 rotor at 90,000g for 2 h. The pellet was collected and resuspended in PBS or saline. Procedures for lentiviral injections into mice were performed according to the NIH guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) at Case Western Reserve University. For virus injection, mice were anesthetized using avertin (250 mg per kg) and placed in a stereotactic frame. A small incision was made to expose the skull surface. Holes were drilled in the skull overlying the motor cortex region (Anterior-Posterior: 1 mm; Medial-Lateral, 1 mm). The needle filled with virus was lowered down 0.7 mm (Dorsal-Ventral) and 2 µl virus (10 9 viral particles per ml) was injected in 5 min. The needle was left in place 5 min before slow withdraw. Skin was sutured, and mice were allowed to recover on warm pads. 1 week after injection, mice were deeply anesthetized with avertin and transcardially perfused with cold PBS. The brain was fixed in paraformaldehyde (4%) for 24 h and then in 30% sucrose for 24 h again. After cryoprotection, the brain coronal sections were cut at 20 µm in thickness for immunostaining. 3-month-old C57BL/6 mice, male or female, were randomly assigned to receiving different injections. The outcomes were independently assessed by an investigator without knowledge of injections.
In vivo administration of TAT peptide. Mice surgery and procedures were performed according to the NIH guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) at Case Western Reserve University. A minimal number of mice were used (at least three per group). C57BL/6 nontransgenic wild-type mice (NTG mice), Prnp-TARDBP mice (TDP-43 WT Tg mice) and Prnp-TARDBP*A315T mice (TDP-43 A315T Tg mice) were purchased from the Jackson Laboratory (Bar Harbor, ME). 2-3-month-old male or female mice were randomly assigned to receiving treatment. Mice were infused subcutaneously with mini-osmotic pumps (Alzet Model 2004, Cupertino, CA; flow rate of 0.25 µl per hour for 10 d). 1 d before implantation, mini-osmotic pumps were filled with 200 µl PBS containing cPM or PM1 peptides (0.5 mg per kg per day), followed by pump incubation in PBS at 37 °C overnight according to the manufacturer's instructions. For surgery, male mice were anesthetized with avertin. A small incision was made at the back of mouse and mini-osmotic pump were implanted subcutaneously. After treatment, mice were deeply anesthetized with avertin and transcardially perfused with cold PBS and spinal cord and brain tissues were collected followed by fractionation, western blot or immunostaining. The outcomes were independently assessed by an investigator without knowledge of treatments.
Motor behavioral assessment. The Rotarod test was used to assay motor coordination and balance of mice using Panlab Rota-Rods (Harvard Apparatus, Holliston, MA) as described 58 . Taken briefly, mice first received training with three trials a day for 3 d (4-12 rpm for less than 3 min with at least 10-min intervals between trials). All mice used in this study reached a stable Rotarod performance after training (data not shown). 3 d after training, mice were assayed at the accelerating mode (4-40 rpm over 5 min) for three times every week. All Rotarod tests were performed with at least 5-min intervals for different genotypes and interspersed to avoid habituation. Footprint analyses were performed using a customized runway (50-cm long, 5-cm wide and both sides bordered). The forepaw and hindpaw of mice were first dipped into red and blue nontoxic paints. Subsequently, mice were placed on the runway covered by white paper, and run into an enclosed dark box. Footprints of sitting mice were not included in quantification. Stride length is the mean distance of forward movement between each stride, and base length is the mean distance between left and right forepaw or hindpaw.
Confocal microscopy, fluorescent microscopy and electron microscopy.
All confocal images were captured at room temperature with a Zeiss LSM 510 inverted laser-scanning confocal fluorescence microscope (controlled through Zeiss LSM 510 confocal software, Zeiss) equipped with a C-Apochromat 40×(1.2W) water objective or alpha Plan-Fluar 100×(1.45) oil objective as previously described 56 . Confocal images of far-red fluorescence were collected npg
